Social Media Ideas for Amgn

Amgen Inc. (AMGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Amgen generated $8.1 billion in free cash flow in 2025, with a 21% net margin, while Axsome is scaling rapidly but still unprofitable.

Amgen: Why Rivals' Cholesterol Drug Fail Is Bad News For The Pharma (Rating Downgrade)

Argenx

Argenx Anonymous (not verified) Mon, 10/19/2026 - 10:14 field_thread_url https://cafepharma.com/boards/threads/argenx.665212/ board name...

Amgen vs. Eli Lilly: Does the GLP-1 Mania Make LLY Stock a Better Buy in 2026?

Amgen trades at half the valuation multiple of Eli Lilly while generating stronger free cash flow, but explosive growth in obesity drugs tells a different story.

Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?

One offers a more affordable entry point while the other boasts some of the highest profit margins in the sector. The choice comes down to whether you prioritize income stability o...

2 Dividend Stocks Crushing the Market in 2026 (and Which Ones Can Keep Going)

These drugmakers are facing some near-term challenges, but is that enough to stop their recent momentum?

Biogen: The Bull Case Is Extending Beyond Alzheimer's (Rating Upgrade)

Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?

Amgen boasts stronger revenue growth, while Bristol Myers Squibb generates nearly 60% more free cash flow at half the valuation.

Axsome rises on Auvelity prescription data

AbbVie, Amgen, Pfizer, GSK among participants in new 340B rebate pilot

Amgen reports a Phase 3 win with Sjögren’s drug candidate

Dazodalibep, acquired in Amgen’s big buyout of Horizon Therapeutics, succeeded in the first of two late-stage trials against the tough-to-treat autoimmune disorder.

Abogen Announces Licensing and Option Agreement with Novartis to Advance mRNA-Encoded T-Cell Engager and other potential...

Includes worldwide license to ABO2203, Abogen's mRNA-encoded CD19xCD3 T-Cell Engager

Trump Admin To Target Biotechs With Curbs On Drug Pricing? What Investors Should Know

ANC

ANC Anonymous (not verified) Mon, 09/14/2026 - 18:53 field_thread_url https://cafepharma.com/boards/threads/anc.712901/ board name...

GLP-1s: Still Early In The Growth Story

<![CDATA[Roundup: Alteogen Enters Option & License Agreement with Novartis, NewBiologix & Synastra Form BioTe...

Biogen upgraded at JPMorgan with $300 PT on 2027 pipeline catalysts, shares rise

Amgen Drug Meets Goals of Key Test in Common Autoimmune Disease With No Approved Meds

Amgen’s dazodalibep led to statistically significant and clinically meaningful results, according to preliminary Phase 3 results in Sjögren’s disease. This fusion protein could com...

<![CDATA[Roundup: AbbVie & Iambic Enter Ai Drug Discovery Collaboration, Telix Merges with ITM ]]>

<![CDATA[M&A Roundup: DualityBio & Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to...

XBI: Big Pharma Can Keep The 76% Rally Going

Genmab

Genmab Anonymous (not verified) Sat, 10/10/2026 - 07:10 field_thread_url https://cafepharma.com/boards/threads/genmab.680642/ board name...

Arrowhead

Arrowhead Anonymous (not verified) Fri, 10/23/2026 - 13:17 field_thread_url https://cafepharma.com/boards/threads/arrowhead.708698/ boar...